Colitis ulcerative

This study tests whether MK-8690, a drug given as a shot, can help people with moderate-to-severe ulcerative colitis achieve remission. About 100 adults who haven't responded well to other treatments will receive either MK-8690 or a placebo. The main goal is to see if more people…

This study looks at the long-term safety of a medicine called tulisokibart for people with moderate to severe Crohn's disease or ulcerative colitis. It is an extension study, meaning participants must have already taken tulisokibart in a previous study. The main goal is to see ho…

This study tests a new medicine called MH002, which contains live bacteria meant to restore gut health in people with mild-to-moderate ulcerative colitis. About 204 adults whose current treatment isn't working well enough will receive either a low dose, high dose, or placebo caps…

This phase 2 study is testing two new drugs — mirikizumab (given by IV or injection) and LY4395089 (a pill) — in 60 adults with moderately to severely active ulcerative colitis or Crohn's disease. The goal is to see if these treatments are safe and can help control the disease. T…

This study observes 35 adults with moderate-to-severe Crohn's disease or ulcerative colitis to see how long they continue taking guselkumab in everyday medical practice. Researchers will track treatment persistence and early symptom relief, like reduced bowel urgency. No experime…

This study will follow 500 people with Crohn's disease or ulcerative colitis who are starting guselkumab, a biologic drug. Researchers will measure how many achieve remission and how the treatment affects daily life, including fatigue and work productivity. The goal is to underst…

This study tests an oral medication called icotrokinra for people with moderate to severe ulcerative colitis, a chronic condition that causes inflammation and ulcers in the colon. About 882 adults and adolescents will receive either the drug or a placebo to see if it can bring ab…

This study tracks 220 adults with moderate-to-severe ulcerative colitis or Crohn's disease who are starting guselkumab, a biologic drug. Researchers will measure how many achieve remission (symptom control) and whether they can stop steroids. The goal is to see how well the drug …

This study follows 200 Chinese patients with moderate-to-severe ulcerative colitis who have never taken biologic drugs. They will receive guselkumab as part of their normal care. Researchers will measure changes in symptoms and quality of life over 48 weeks to see how well the dr…

This phase 3 trial tests whether the experimental drug JNJ-78934804 can help people with moderate to severe ulcerative colitis achieve remission better than the existing drug guselkumab. About 644 participants will receive either the new drug or guselkumab, and researchers will c…

This study is checking the long-term safety of guselkumab, a biologic drug given as a shot, in children with moderate to severe Crohn's disease, ulcerative colitis, or juvenile psoriatic arthritis. About 196 kids who already completed a prior guselkumab study and benefited from i…

This Phase 2 trial is testing three long-acting antibodies, alone or in combination, for people with moderate-to-severe ulcerative colitis. The study will enroll 645 adults to see if these treatments can reduce inflammation and lead to remission. Participants receive the antibodi…

This study tests a daily pill called etrasimod in 24 children aged 2 to 12 with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. The goal is to see if the drug can safely help children reach remission (few or no symptoms) over 52 weeks. Participants wh…

This study tests an oral medication called ozanimod in children aged 12-17 with moderate-to-severe ulcerative colitis who haven't responded to standard treatments. The goal is to see if the drug can safely bring the disease into remission. About 120 participants will receive eith…

This study watches 300 adults with moderate to severe ulcerative colitis who are prescribed etrasimod by their doctor. Researchers track symptoms like stool frequency and rectal bleeding over 52 weeks using health questionnaires. The goal is to see how well the drug works outside…

This study is monitoring the safety and effectiveness of the drug Jyseleca (filgotinib) in Korean patients with rheumatoid arthritis or ulcerative colitis. Researchers will track side effects and disease activity over 24 weeks. About 2,040 participants are being observed during r…

This study follows 50 people with moderate to severe Crohn's disease or ulcerative colitis to see how long they stay on guselkumab in real-world settings. Researchers will measure treatment persistence and early symptom improvements using patient diaries. The goal is to understan…

This program provides early access to the drug etrasimod for people with ulcerative colitis who have tried at least three other treatments without success or cannot use them. The goal is to offer a potential treatment option when no standard therapies are left. Patients must meet…

This study tests whether a carefully designed diet can change the gut bacteria in people with active ulcerative colitis and reduce disease activity. Twenty adults with mild to moderate colitis will follow the diet and have their gut bacteria and inflammation levels measured. The …

This trial asks whether adding a quick, painless intestinal ultrasound to standard check-ups can change how doctors treat inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Adults with IBD who are already scheduled for a colonoscopy are randomly a…

This study is testing a device called the AlgometRx Nociometer to see if it can measure inflammation in children with inflammatory bowel disease (IBD). The device checks how different nerve fibers respond, which may give doctors a clearer picture of disease activity. Researchers …

This study looks at the long-term safety of the drug ustekinumab compared to other biologic treatments in adults with Crohn's disease or ulcerative colitis. Researchers will use health records from the Department of Defense to track rates of cancer, serious infections, and other …

This study will measure how much of the drug TREMFYA (guselkumab) passes into breast milk of 10 nursing women who are already taking it for conditions like psoriasis, psoriatic arthritis, ulcerative colitis, or Crohn's disease. Researchers will collect milk samples to estimate th…

This study looks at how children with Crohn's disease or ulcerative colitis burn energy at rest. Researchers will measure resting energy expenditure using a special breathing test and compare it to standard formulas. The goal is to see if energy use is linked to disease activity …

This study from Aarhus University is looking at how common magnesium deficiency is in people with Crohn's disease, ulcerative colitis, ileostomy, or bile acid diarrhea. Magnesium is important for muscles, nerves, and heart health, but standard blood tests may miss a deficiency. T…

This study looks at how sleep problems affect people with ulcerative colitis, a type of inflammatory bowel disease. Researchers will study 152 participants to see how sleep quality relates to gut bacteria, nerve function, and disease activity. The goal is to understand the connec…